Amgen Inc. $AMGN Stock Acquired by Wedmont Private Capital

Wedmont Private Capital increased its position in Amgen Inc. (NASDAQ:AMGN) by 33.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 11,577 shares of the medical research company’s stock after purchasing an additional 2,911 shares during the period. Wedmont Private Capital’s holdings in Amgen were worth $4,717,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Intelligence Driven Advisers LLC increased its stake in Amgen by 4.0% in the 3rd quarter. Intelligence Driven Advisers LLC now owns 926 shares of the medical research company’s stock valued at $390,000 after buying an additional 36 shares during the period. Journey Retirement Planning & Investment Management LLC purchased a new position in shares of Amgen during the 3rd quarter valued at $248,000. O Keefe Stevens Advisory Inc. grew its holdings in shares of Amgen by 1.0% during the 3rd quarter. O Keefe Stevens Advisory Inc. now owns 52,256 shares of the medical research company’s stock valued at $22,027,000 after acquiring an additional 504 shares in the last quarter. Legacy Wealth Asset Management LLC increased its stake in shares of Amgen by 79.4% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,657 shares of the medical research company’s stock worth $1,963,000 after acquiring an additional 2,061 shares during the last quarter. Finally, Market Street Wealth Management Advisors LLC acquired a new position in shares of Amgen in the third quarter worth $304,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on AMGN. Morgan Stanley reduced their price objective on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research report on Wednesday. Jefferies Financial Group reiterated a “hold” rating and set a $410.00 price target on shares of Amgen in a report on Wednesday, September 23rd. Guggenheim boosted their price target on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. TD Cowen increased their price objective on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $389.71.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 2.3%

NASDAQ AMGN traded up $9.23 during trading on Friday, hitting $416.67. 765,308 shares of the company traded hands, compared to its average volume of 2,746,166. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03. The business has a fifty day simple moving average of $412.35 and a 200 day simple moving average of $371.88. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $225.26 billion, a P/E ratio of 25.87, a PEG ratio of 2.98 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s payout ratio is 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: An analyst upgrade helped drive buying interest in Amgen, with reports indicating the stock rose about 3% following the rating change. Amgen Stock Price Up 3% on Analyst Upgrade
• Positive Sentiment: Cantor Fitzgerald raised its price target for AMGN from $400 to $440, signaling greater confidence in Amgen’s earnings outlook and pipeline prospects. The target increase is a notable bullish catalyst, though it still leaves limited upside if shares remain near recent levels. Cantor Fitzgerald Raises Amgen Price Target
• Positive Sentiment: Amgen announced a head-to-head Phase 3 trial of its monthly diabetes treatment against semaglutide. Success could give the company a significant opportunity in the competitive GLP-1 market and provide a longer-term growth catalyst. Amgen Diabetes Drug Phase 3 Trial
• Positive Sentiment: The company also reported results from a Sjögren’s syndrome trial and participated in a $30 million Series A investment in AI-based genetic testing, potentially strengthening its research and precision-medicine capabilities. Amgen AI Genetic Testing Investment
• Neutral Sentiment: Morgan Stanley maintained a Hold rating, while its price target was reduced slightly from $362 to $359. This provides a counterpoint to Cantor Fitzgerald’s bullish view and suggests analyst opinion remains divided. Morgan Stanley Hold Rating on Amgen

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.